...
首页> 外文期刊>Journal of the American Society of Nephrology: JASN >Spectrum of Mutations in the Gene for Autosomal Recessive Polycystic Kidney Disease (ARPKD/PKHD1).
【24h】

Spectrum of Mutations in the Gene for Autosomal Recessive Polycystic Kidney Disease (ARPKD/PKHD1).

机译:常染色体隐性隐性多囊肾疾病(ARPKD / PKHD1)基因突变的光谱。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

ABSTRACT. Autosomal recessive polycystic kidney disease (ARPKD/PKHD1) is an important cause of renal-related and liver-related morbidity and mortality in childhood. Recently mutations in the PKHD1 gene on chromosome 6p21.1-p12 have been identified as the molecular cause of ARPKD. The longest continuous open reading frame (ORF) is encoded by a 67-exon transcript and predicted to yield a 4074-amino acid protein ("polyductin") of thus far unknown function. By now, a total of 29 different PKHD1 mutations have been described. This study reports mutation screening in 90 ARPKD patients and identifies mutations in 110 alleles making up a detection rate of 61%. Thirty-four of the detected mutations have not been reported previously. Two underlying mutations in 40 patients and one mutation in 30 cases are disclosed, and no mutation was detected on the remaining chromosomes. Mutations were found to be scattered throughout the gene without evidence of clustering at specific sites. About 45% of the changes were predicted to truncate the protein. All missense mutations were nonconservative, with the affected amino acid residues found to be conserved in the murine polyductin orthologue. One recurrent missense mutation (T36M) likely represents a mutational hotspot and occurs in a variety of populations. Two founder mutations (R496X and V3471G) make up about 60% of PKHD1 mutations in the Finnish population. Preliminary genotype-phenotype correlations could be established for the type of mutation rather than for the site of the individual mutation. All patients carrying two truncating mutations displayed a severe phenotype with perinatal or neonatal demise. PKHD1 mutation analysis is a powerful tool to establish the molecular cause of ARPKD in a given family. Direct identification of mutations allows an unequivocal diagnosis and accurate genetic counseling even in families displaying diagnostic challenges. E-mail: cbergmann@ukaachen.de
机译:抽象。常染色体隐性隐性多囊肾病(ARPKD / PKHD1)是儿童肾相关和肝相关发病率和死亡率的重要原因。最近,已经鉴定出染色体6p21.1-p12上PKHD1基因的突变是ARPKD的分子原因。最长的连续开放阅读框(ORF)由67个外显子转录物编码,并预测会产生迄今功能未知的4074个氨基酸的蛋白质(“多导蛋白”)。到目前为止,已经描述了总共29种不同的PKHD1突变。这项研究报告了90位ARPKD患者的突变筛查,并鉴定了110个等位基因的突变,检出率为61%。以前没有报道过34种检测到的突变。公开了40位患者的两个潜在突变和30位患者的一个突变,并且在其余染色体上未检测到突变。发现突变分散在整个基因中,而没有在特定位点聚集的证据。预计约有45%的变化会截断蛋白质。所有的错义突变都是非保守的,受影响的氨基酸残基在鼠类多导素直向同源物中是保守的。一个复发性错义突变(T36M)可能代表突变热点,并发生在多种人群中。在芬兰人群中,两个创始人突变(R496X和V3471G)构成了PKHD1突变的大约60%。可以为突变类型而不是单个突变位点建立初步的基因型-表型相关性。所有携带两个截短突变的患者均表现出严重的表型,并伴有围生期或新生儿死亡。 PKHD1突变分析是确定给定家族中ARPKD分子原因的强大工具。对突变的直接鉴定即使在显示诊断挑战的家庭中也可以进行明确的诊断和准确的遗传咨询。电子邮件:cbergmann@ukaachen.de

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号